代谢的十字路口:解开免疫细胞动态在胃肠癌药物耐药性
Chahat Suri1, Babita Pande2, Lakkakula Suhasini Sahithi3
1Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton AB T6G 1Z2, Canada.
Cancer drug resistance (Alhambra, Calif.)
|March 7, 2025
概括
在胃肠道 (GI) 癌症中,代谢重编程通过改变瘤微环境 (TME) 代谢来驱动药物耐药性. 向脂肪酸氧化和糖解可以克服耐药性并提高免疫治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 免疫学 免疫学 免疫学
背景情况:
- 瘤微环境 (TME) 中的代谢重编程对于胃肠 (GI) 癌症中耐药性至关重要.
- 癌细胞改变新陈代谢 (脂肪酸氧化,糖解) 来支持生长并产生免疫抑制的TME.
- 在TME中的免疫细胞也经历了代谢变化,采用了抑制免疫的表型,阻碍了抗瘤反应并降低了治疗的有效性.
研究的目的:
- 探索代谢重编程在胃肠道癌药物耐药性中的作用.
- 研究癌症和免疫细胞代谢如何在TME中相互作用.
- 确定针对代谢途径的治疗策略,以克服耐药性并改善治疗结果.
主要方法:
- 分析代谢途径,包括脂肪酸氧化和肠胃癌中的糖解.
- 癌症和免疫细胞之间的营养竞争 (例如葡萄糖) 的研究.
- 评估代谢副产品 (乳酸盐,金氨酸) 和它们对免疫细胞的影响.
主要成果:
- 代谢重编程,特别是脂肪酸氧化和糖解,是肠道癌症中耐药性的关键驱动因素.
- 改变的TME代谢,包括营养物质的枯竭和酸度,会损害抗瘤免疫力.
- 代谢副产品促进免疫抑制细胞 (调节性T细胞,M2巨细胞) 和妥协效应T细胞功能.
结论:
- 针对脂肪酸氧化和糖解提供了一个有希望的策略,以克服胃肠道癌症的耐药性.
- 调节TME新陈代谢可以重振抗瘤免疫力,提高免疫疗法的有效性.
- 未来的研究应该专注于代谢抑制剂,组合疗法,以及肠胃癌患者分层的生物标志物.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K


